CN117462527A - Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets - Google Patents
Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets Download PDFInfo
- Publication number
- CN117462527A CN117462527A CN202211712037.8A CN202211712037A CN117462527A CN 117462527 A CN117462527 A CN 117462527A CN 202211712037 A CN202211712037 A CN 202211712037A CN 117462527 A CN117462527 A CN 117462527A
- Authority
- CN
- China
- Prior art keywords
- oil
- injection
- gabexate mesylate
- pancreatitis
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950000501 gabexate Drugs 0.000 title claims abstract description 67
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 65
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title abstract description 13
- 229940079593 drug Drugs 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
- 238000002347 injection Methods 0.000 claims description 44
- 239000007924 injection Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003921 oil Substances 0.000 claims description 33
- 235000019198 oils Nutrition 0.000 claims description 33
- 239000012071 phase Substances 0.000 claims description 33
- 239000002960 lipid emulsion Substances 0.000 claims description 27
- 239000008215 water for injection Substances 0.000 claims description 13
- 235000021323 fish oil Nutrition 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 210000003022 colostrum Anatomy 0.000 claims description 10
- 235000021277 colostrum Nutrition 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 238000010008 shearing Methods 0.000 claims description 9
- 208000030852 Parasitic disease Diseases 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 208000037280 Trisomy Diseases 0.000 claims description 5
- 208000003167 cholangitis Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 210000003445 biliary tract Anatomy 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 206010027423 Metabolic alkalosis Diseases 0.000 claims description 2
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 229940121657 clinical drug Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 53
- 241000282472 Canis lupus familiaris Species 0.000 description 28
- 241000282326 Felis catus Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- 210000000496 pancreas Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 230000008673 vomiting Effects 0.000 description 10
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000711506 Canine coronavirus Species 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 241000282324 Felis Species 0.000 description 6
- 102000004882 Lipase Human genes 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 6
- 239000004367 Lipase Substances 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000019421 lipase Nutrition 0.000 description 6
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- 241000223836 Babesia Species 0.000 description 5
- 241000701931 Canine parvovirus Species 0.000 description 5
- 201000008680 babesiosis Diseases 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010033647 Pancreatitis acute Diseases 0.000 description 4
- 201000003229 acute pancreatitis Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008236 heating water Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 241000712083 Canine morbillivirus Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000869417 Trematodes Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000003102 mental depression Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000223846 Babesia canis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- ODIKWUKMZQURDR-UHFFFAOYSA-N CS(O)(=O)=O.CCOC(=O)C1=CC=CC=C1 Chemical compound CS(O)(=O)=O.CCOC(=O)C1=CC=CC=C1 ODIKWUKMZQURDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 1
- 206010033627 Pancreatic injury Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 208000005098 feline infectious peritonitis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LKRWBLLGEAXPRY-UHFFFAOYSA-N metronidazole sodium Chemical compound [Na+].CC1=NC=C([N+]([O-])=O)N1CC[O-] LKRWBLLGEAXPRY-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an application of gabexate mesylate in preparing a pharmaceutical preparation for treating pancreatitis of pets, and belongs to the field of application of chemical drugs for animals. The pharmaceutical preparation comprises gabexate mesylate serving as an active ingredient and one or more than one pharmaceutical auxiliary material, can effectively treat pancreatitis and pancreatitis complications of pets caused by factors such as parasites or virus infection, and has the advantages of outstanding prevention and treatment effects and good bioavailability.
Description
Technical Field
The invention belongs to the technical field of veterinary chemical drug application, and particularly relates to application of gabexate mesylate in preparation of drugs for treating pancreatitis of pets.
Background
Pancreatitis is an inflammatory reaction that stimulates pancreatic tissues to secrete pancreatic digestive enzymes to digest the pancreas itself under the action of certain pathogenic factors, so that the pancreatic tissues exhibit edema, hemorrhage and necrosis as main pathological changes. Inflammation of pancreatitis is inflammatory cell infiltration, typically a sterile inflammatory process.
Canine pancreatitis is an inflammatory reaction that is activated in the pancreas by various digestive enzymes secreted by exocrine pancreatic tissue, causing self-digestion and hydrolysis of the pancreas, causing damage to pancreatic tissue [ Yang Shoushen, lin Aihua, tang Runbin, etc. ] canine pancreatitis clinical characterization survey and treatment [ J ]. Black longjiang animal doctor, 2021 (2): 87-91, 97.]. Clinically, acute Pancreatitis (AP) is a common occurrence, and causes hyperlipidemia and infectious diseases (such as canine parvovirus, coronavirus and parasitic infection) caused by overeating and hormone abuse are mainly caused [ chikungunya, huang Xujun. Diagnosis and treatment of pancreatitis secondary to canine parvovirus disease [ J ]. Journal of chinese veterinarian, 2014, 50 (5): 72-74.].
Most of the diseases of the cat pancreatitis are caused by the special physiological structure of the cat pancreas, and fatty liver and biliary tract diseases (such as cholangitis, biliary tract obstruction and inflammatory bowel disease) are often accompanied with the occurrence of pancreatitis; pancreatitis is also often caused by blockage of pancreatic ducts (e.g., tumors), inflammatory bowel disease. Ischemia, hypercalcemia, and hypertriglyceridemia of the body due to hypotension or anesthesia are also one of the causes of pancreatitis. Many drugs and toxins are also believed to be associated with feline pancreatitis, such as organophosphates, esters, calcium, and the like. Other risk factors associated with feline pancreatitis include blunt trauma (e.g., car accident, high building syndrome), surgical trauma, parasitic infection (e.g., toxoplasmosis, trematodes), and infectious pathogen infection (e.g., feline calicivirus, feline infectious peritonitis virus, feline plague, and feline herpes virus), among others.
The clinical symptoms of the canine and feline pancreatitis are not specific, the clinical diagnosis is difficult, and misdiagnosis and missed diagnosis are easy to occur. At present, the general principles of treatment of the canine and feline pancreatitis are to correct water-salt balance, inhibit secretion of gastric acid and other glands, relieve pain, stop vomiting, prevent shock, prevent infection and the like. The incidence of canine cat pancreatitis has shown an increasing trend in recent years, however, there is a substantial difference between the causative cause of canine cat pancreatitis and the causative cause of human pancreatitis; and the physiological functions, the metabolic characteristics and the like of the human body and the dogs and cats are essentially different, the mutual technical difficulty of the human body medication and the dogs and cats medication exists, and no related report on the special gabexate mesylate product for dogs and cats exists at present.
Gabexate mesylate (Gabexate mesilate) is a serine protease inhibitor, and has a chemical name of p- (6-guanidine acetoxy) ethyl benzoate mesylate and a molecular formula of C 16 H 23 N 3 O 4 ·CH 4 O 3 S or C 17 H 27 N 3 O 7 S, molecular weight 417.48CAS number: 56974-61-9, and has the following structural formula.
Gabexate mesylate has the structural formula:
the research at home and abroad proves that the gabexate mesylate can inhibit the activities of protease such as trypsin, kallikrein, plasmin, thrombin and the like, thereby preventing the pathophysiological changes caused by the protease. In animal experimental acute pancreatitis, activated trypsin can be inhibited, pancreatic injury is relieved, and simultaneously, the activity of serum starch alcohol, lipase and urea nitrogen are obviously improved, and gabexate mesylate is used for preparing medicaments for treating acute light (oedema) pancreatitis and assisting in treating acute hemorrhagic necrosis type pancreatitis, but the gabexate mesylate products prepared by the methods are all taken by people, and due to the fact that physiological functions, metabolic characteristics and the like of people and dogs and cats are essentially different, no related report and research on the gabexate mesylate products special for dogs and cats exist at present.
Disclosure of Invention
Based on the problems existing in the practice, the invention provides application of gabexate mesylate in preparing a pharmaceutical preparation for treating pancreatitis of pets and complications of pancreatitis of pets.
In a first aspect, the invention provides the use of gabexate mesylate in the manufacture of a pharmaceutical formulation for the treatment of pancreatitis in pets.
The pharmaceutical preparation comprises gabexate mesylate serving as an active ingredient and one or more than one medicinal auxiliary material.
The pet is a dog or cat.
The pancreatitis of the pet is caused by one or more of pancreatic susceptibility, parasitic infectious diseases, veterinary clinical medicine factors, virus infectious diseases and the like caused by special dietary structures or pancreas physiological structures of the pet.
Preferably, the pancreatitis in pets is caused by a parasitic infectious disease, a viral infectious disease.
Preferably, the parasitic infectious diseases include parasitic infections of babesia, toxoplasma, trematodes and the like.
Preferably, the viral infectious diseases include parvoviral infectious diseases, coronavirus infectious diseases, feline infectious peritonitis, and the like.
Preferably, the veterinary clinical drug factor includes hormone abuse, anesthesia complications, and the like.
In a second aspect, the invention provides the use of gabexate mesylate in the manufacture of a pharmaceutical formulation for the treatment of complications of pancreatitis in pets.
The complications of the pancreatitis of the pets are one or more of cholangitis, biliary tract obstruction, inflammatory bowel disease, metabolic alkalosis and catarrhal inflammation.
The gabexate mesylate pharmaceutical preparation for treating pancreatitis and pancreatitis complications of pets can be administered by intravenous, local perfusion in biliary tract, intramuscular or subcutaneous and oral routes, preferably intravenous administration.
Preferably, the pharmaceutical preparation for treating pancreatitis and pancreatitis complications of pets is gabexate mesylate freeze-dried powder injection or gabexate mesylate injection.
More preferably, the pharmaceutical preparation is gabexate mesylate fat emulsion injection.
The administration dosage of the gabexate mesylate fat emulsion injection is 2-6 mg/kg.
In a third aspect, the invention provides a gabexate mesylate fat emulsion injection which consists of gabexate mesylate, oil for injection, lecithin, glycerol and water for injection.
The fat emulsion injection comprises the following components in percentage by mass and volume: 1.0 to 3.0 percent of gabexate mesylate, 8 to 30 percent of oil for injection, 0.5 to 2.0 percent of lecithin and 3 to 10 percent of glycerol, and the water for injection is supplemented to 100 percent.
Preferably, the fat emulsion injection comprises the following components in percentage by mass and volume: 1.5 to 2.5 percent of gabexate mesylate, 8.0 to 15.0 percent of oil for injection, 1.0 to 2.0 percent of lecithin, 3.0 to 5.0 percent of glycerol and 100 percent of water for injection.
More preferably, the fat emulsion injection comprises the following components in percentage by mass and volume: gabexate mesylate 2.0%, oil for injection 15%, lecithin 2%, glycerol 4%, and water for injection 100%.
The oil for injection is one or more selected from soybean oil, olive oil, safflower oil, sesame oil, coconut oil, castor oil, fish oil, medium chain monoglyceride, medium chain diglyceride and medium chain triglyceride.
Preferably, the oil for injection is one or more selected from fish oil, medium chain triglyceride, soybean oil and castor oil.
More preferably, the oil for injection is selected from one or two of fish oil and medium chain triglycerides.
Preferably, the lecithin is egg yolk lecithin.
The invention provides a preparation method of gabexate mesylate fat emulsion injection, which comprises the following steps:
(1) Preparing an oil phase: weighing the gabexate mesylate and the oil for injection according to the prescription, adding lecithin, heating to 70-90 ℃, and stirring and dissolving to obtain an oil phase;
(2) Preparing an aqueous phase: weighing the glycerol and the water for injection according to the prescription, heating to 70-90 ℃, stirring and dissolving to obtain a water phase;
(3) Under the heat preservation condition of 70-90 ℃, adding the oil phase into the water phase while shearing at 7000rpm, and shearing for 20min after the addition is finished, thus forming the colostrum. The colostrum is passed through a high-pressure homogenizer for 2 times, and the pressure is 800-1200 bar, so as to obtain emulsion. Packaging into penicillin bottles, filling nitrogen, sealing, and rotary sterilizing to obtain the final product.
The beneficial effects are that:
1. the invention provides application of gabexate mesylate in preparing a pharmaceutical preparation for preventing and treating pancreatitis and pancreatitis complications of pets, in particular dogs and cats, wherein the dosage of the gabexate mesylate in treating pancreatitis and pancreatitis complications of cats is specifically 2-6 mg/kg, and when the gabexate mesylate is administrated to a pet intravenous drip for suffering from pancreatitis, the clinical effect is obvious, and the gabexate mesylate is a medicament with better treatment and prevention effects, which is suitable for the pancreatitis of dogs and cats and the complications thereof.
2. The fat emulsion injection containing the gabexate mesylate is used in the treatment process of canine and feline pancreatitis caused by specific causes, can inhibit the activities of protease such as trypsin, kallikrein, plasmin, thrombin and the like so as to reduce pancreas injury, and can obviously improve the activities of serum amylase and lipase and abnormal rise of urea nitrogen.
3. The fat emulsion is mixed fat emulsion, has better organism metabolism and tolerance, and has a certain function of regulating organism immunity. The injection oil in the formula is a mixture of fish oil and medium chain triglycerides, wherein the fish oil is rich in omega-3 polyunsaturated fatty acids, and has more excellent effects of reducing inflammatory reaction and regulating immunity. Compared with the traditional vegetable oil, the medium chain triglyceride has better antioxidation stability and drug solubility, is not easy to cause the increase of blood fat, and reduces the incidence rate of adverse reaction.
Detailed description of the preferred embodiments
The foregoing will be described in further detail by way of the following detailed description of the embodiments. It should not be construed that the scope of the above subject matter is limited to the following examples. All techniques implemented based on this disclosure are within the scope.
Example 1
The preparation method of the gabexate mesylate fat emulsion injection comprises the following steps:
preparing an oil phase: adding gabexate mesylate and fish oil into egg yolk lecithin according to a group Fang Liangqu, heating to 90 ℃, and stirring and dispersing to obtain the additive; preparing an aqueous phase: adding glycerol into appropriate amount of injectable water, stirring for dissolving, and heating to 90deg.C; mixing the oil phase and the water phase, stirring, adding injectable water to a preparation amount, shearing at 7000rpm for 30min to form colostrum, adding gabexate sulfonate with final concentration of 2.1% (w/v), homogenizing at 1000bar pressure for 2 times to obtain emulsion, packaging into penicillin bottles, sealing, and sterilizing to obtain fat emulsion.
The formula list is as follows:
| formulation prescription | Proportion of |
| Gabexate mesylate | 2.0％w/v |
| Fish oil | 12.0％w/v |
| Egg yolk lecithin | 1.5％w/v |
| Glycerol | 5.0％w/v |
| Water for injection | To 100% |
Example 2
Heating water for injection to 80deg.C, adding glycerol, and dissolving to obtain water phase; heating fish oil and medium chain triglyceride to 80deg.C, adding egg yolk lecithin and gabexate mesylate, and stirring to dissolve to obtain oil phase; adding the oil phase into the water phase, adding water for injection, controlling the temperature in water bath to 80 ℃, shearing at 7000rpm at high speed, and dispersing for 30min to form colostrum; homogenizing at 1000bar under high pressure for 2 times, filtering, bottling, and sterilizing.
The formula list is as follows:
example 3
The preparation method of the gabexate mesylate fat emulsion injection comprises the following steps:
heating water for injection to 75deg.C, adding glycerol for dissolution, and collecting water phase; heating fish oil and medium chain triglyceride to 75deg.C, adding egg yolk lecithin and gabexate mesylate, stirring to dissolve, and taking the mixture as oil phase; adding the oil phase into the water phase, adding water for injection, controlling the temperature in water bath at 75deg.C, shearing at 7000rpm at high speed for 30min, and dispersing to obtain colostrum; homogenizing at 1000bar under high pressure for 2 times, filtering, bottling, and sterilizing.
The formula list is as follows:
| formulation prescription | Proportion of |
| Gabexate mesylate | 2.0％w/v |
| Fish oil | 5.0％w/v |
| Medium chain triglycerides | 10.0％w/v |
| Egg yolk lecithin | 2.0％w/v |
| Glycerol | 4.0％w/v |
| Water for injection | To 100% |
Example 4
The preparation method of the gabexate mesylate fat emulsion injection comprises the following steps:
heating water for injection to 70deg.C, and adding glycerol to dissolve to obtain water phase; heating medium chain triglyceride to 70deg.C, adding egg yolk lecithin and gabexate mesylate, and stirring to dissolve to obtain oil phase; adding the oil phase into the water phase, adding injection water, controlling the temperature in water bath to 70 ℃, shearing at 7000rpm at high speed, and dispersing for 30min to form colostrum; homogenizing at 1000bar under high pressure for 2 times, filtering, bottling, and sterilizing.
The formula list is as follows:
example 5
The preparation method of the gabexate mesylate fat emulsion injection comprises the following steps:
heating water for injection to 60deg.C, and adding glycerol to dissolve to obtain water phase; heating oleum Olivarum to 60deg.C, adding egg yolk lecithin and gabexate mesylate, and stirring to dissolve to obtain oil phase; adding the oil phase into the water phase, adding injection water, controlling the temperature in water bath at 60 ℃, shearing at 7000rpm at high speed, and dispersing for 30min to form colostrum; homogenizing at 1000bar under high pressure for 2 times, filtering, bottling, and sterilizing.
The formula list is as follows:
| formulation prescription | Proportion of |
| Gabexate mesylate | 2.0％w/v |
| Olive oil | 10.0％w/v |
| Egg yolk lecithin | 1.5％w/v |
| Glycerol | 4.5％w/v |
| Water for injection | To 100% |
Example 6 test for detecting Properties of fat emulsion injection
Key indexes of gabexate mesylate fat emulsion injection obtained in examples 1 to 5 were detected, and the results are shown in the following table:
the gabexate mesylate fat emulsion injection prepared in the present examples 1 to 4 was subjected to particle size, zeta potential and pH detection, and the detection results were: the average grain diameter is 184-218 nm,90% of particles are less than or equal to 273nm, the Zeta potential is-53-61 mV, and the pH value is 6.5-7.0. The water phase temperature is controlled at 70-90 ℃, the oil phase temperature is controlled at 70-90 ℃, the primary emulsion temperature is controlled at 70-90 ℃, and the homogenization temperature is 35-50 ℃, so that the particle size and the distribution of the prepared samples have no obvious difference in Zeta potential. On the premise of the temperature control range of the invention, the change of temperature has no obvious influence on the Zeta potential, the average particle size and the distribution of the emulsion, and the product quality is stable.
Particle size, zeta potential and pH value of the gabexate mesylate fat emulsion injection prepared in example 5 are detected, and the detection result is as follows: the average grain diameter is 275-293 nm,90% of the grains are less than or equal to 393nm, the pH value is 6.0-6.9, and the Zeta potential is-27-32 mV. As can be seen from the comparison of the data in examples 5 and examples 1 to 4, the oil for injection, the water phase temperature, the oil phase temperature, the homogenization temperature of the colostrum and the microfluidics are different from those in examples 1 to 4, the average particle size of the product is larger, the distribution of emulsion particles is wider, and the stability is slightly poor.
Example 7 treatment of pancreatitis caused by babesia in pet dogs
On day 8 and 15 of 2022, the hospital received 1 female tady dogs, 5 months of age 2, and 2.95kg of body weight. The sick dogs were immunized according to immunization program, near 3d mental retardation, diarrhea, a small amount of blood filaments in the feces, vomiting 1 time a day, high abdominal tension, and no contact. The skin on the body surface is marked with biting marks, and the owner is informed of travel from dogs to villages by 2 months.
Clinical examination: it is found that the sick dogs have mental depression, visual mucosa yellow staining, nasal mirror dryness and body temperature of 39.7 ℃. Palpation of the abdomen is painful, the anus is contaminated by faeces, and the anus is slightly dehydrated. Laboratory examination: CCV detection and babesia examination were performed based on clinical symptoms combined with immunization. The canine coronavirus detection was performed first, showing negative. Blood was collected for smear microscopy and blood examination, stained with Diff's quick stain, and examined under a 100-fold microscope to visualize punctiform Babesia gibsonii.
Babesia canis disease is generally transmitted by ectoparasite ticks, primarily affecting erythrocytes, causing hemolysis and anemia, which can induce pancreatitis.
The doctor holds the affected dogs on the back, shaves the abdominal hair and performs color ultrasound examination. The results showed that the pancreas region was hypoechoic and the bile duct was dilated. Color Doppler ultrasound indicates that the pancreas is damaged. The test is carried out by adopting Edison cPL rapid detection test paper, and the result is positive, so that the dog is prompted to suffer from pancreatitis.
The treatment principle is as follows: controlling primary disease, replenishing blood, correcting acid-base and electrolyte balance, improving resistance, relieving pain, stopping vomiting, inhibiting enzyme activity, and preventing secondary infection. The prescription is as follows: intravenous injection: (1) 30ml of 0.9% sodium chloride solution + 150mg of ampicillin; (2) 50ml of 0.9% sodium chloride solution+gabexate mesylate 12mg (example 1); (3) 0.5mLVc,0.3mLATP,0.3mLCOA,0.3mLVB were added to a 5% glucose solution; subcutaneous injection: (4) 11mg of triazamidine; (5) blood-rich gram 0.5ml; (6) 0.3ml of anti-emetic agent.
After the treatment by the method, the Edison cPL rapid test paper is detected again after 4 days, and the test result is negative, which indicates that the plasma specific lipase value is recovered to the normal level. After 1 week the sick dogs were gradually improved and the mental appetite recovered, and after 1 month the dogs were rechecked as negative for babesia.
Example 8 treatment of pancreatitis caused by pet canine coronavirus
1 white male was older than Xiong Quan, 1 year, 4.5kg, sterilized, normally insect repellent, incompletely immunized, 10 months of 2022, 17 days ago for clinic. Complaints: the sick dogs eat chicken and milk in noon in 10 months and 16 days, begin to vomit (3-4 times) after a while, relieve the bowels for 2 times, and the feces are hard and thin after each other; the following day no food was taken.
Clinical examination: the body temperature of the affected dogs is 39 ℃, visual mucous membrane is pale, eyeballs are depressed, nasal lenses are dry, spirit is depressed, and the dogs are reluctant to move; vomit is undigested food and yellow mucus; the feces are water-like and green.
Laboratory examination: a small amount of feces of a dog is taken, and the results are tested by using a Canine Coronavirus (CCV), canine Parvovirus (CPV) and Canine Distemper Virus (CDV) antigen rapid test card, so that CCV (+), CPV (original) and CDV (original) are shown. The anterior extremity vein of the affected dog is used for blood biochemistry and canine pancreatitis rapid detection test paper (cPL) examination. Albumin content decreases, suggesting bowel disease; the amylase activity was greatly increased, suggesting acute pancreatitis. The test is carried out by adopting Edison cPL rapid detection test paper, and the result is positive, so that the dog is prompted to suffer from pancreatitis.
The established treatment principles are antiviral, anti-inflammatory and symptomatic treatment and the like (intravenous injection, continuous administration for 7 d) aiming at the actual situation of the suffering dogs: (1) 20mL of 0.9% sodium chloride solution plus 0.45g of ampicillin sodium plus 1.0mL of ribavirin; (2) 25mL of metronidazole sodium chloride; (3) 20mL of 0.9% sodium chloride solution+inosine 1.0mL; (4) 40mL of 5% glucose solution and 1 branch of water-soluble vitamin; (5) 30mL of 5% glucose solution+ATP2.0mL; (6) 30mL of 5% glucose solution+18 mg of gabexate mesylate (example 3); (7) 40mL of 5% glucose solution+5.0 mL of life element; (8) 40mL of 5% glucose solution+2.5 mL of Sai Te long; (9) 0.45mL of anti-emetic; canine IFN-alpha 200 ten thousand IU. After 1 week of treatment, the activities of serum amylase and lipase are recovered to be normal, the vomiting of the suffering dogs is stopped, the feces are formed, the spirit is good, and the appetite is improved. The owner brings home, and the doctor orders to pay attention to diet, so that stress is reduced. After 2 weeks, the dogs were informed by telephone return visit, had a lively mind, had good appetite, had normal urination and recovery.
In the case, canine pancreatitis is probably caused by canine coronavirus diseases, various digestive enzymes secreted by exocrine pancreatic tissues are activated in pancreas, so that pancreas self-digestion and hydrolysis are caused, pancreatic tissues are damaged, and the canine pancreatitis is treated by gabexate mesylate, and inosine, ATP, vital elements and other medicaments are used for supplementing energy for organisms, and meanwhile, the canine pancreatitis is fasted, water-forbidden, antibacterial and anti-inflammatory. After 1 week of treatment, the vomiting of the suffering dogs is stopped, the feces are formed, the spirit is good, the appetite is improved, and the diagnosis and treatment are reasonable.
Canine coronavirus diarrhea is a serious hazard to puppies, but death is rare with the age of dogs and the sudden advance of modern medical level. However, if a plurality of viruses are mixed and infected, the healing difficulty is greatly improved, and the situation of internal diseases such as parasitic diseases, pancreatitis and the like is more common.
EXAMPLE 9 treatment of pancreatitis caused by trisomy in pet cats
Short cat, 2 years old, male (castrated), 2.8kg body weight, complete history of vaccine. The pet owner complains about the foam floor mat by mistake 1 month before suffering from the cat, and then continuously takes the vomiting symptom, and the pet owner drenches probiotics at home, and does not see symptom relief until 4 days before seeing a doctor, and the appetite is abolished.
Clinical examination: suffering from mental depression, vomiting and anorexia, three-stage dehydration, no diarrhea, abdominal pain before palpation, visual pale yellow and stained mucous membrane, capillary refill time of 4s, body temperature of 37.6 ℃, breathing 40 times/min, and heart rate 190 times/min.
Color Doppler ultrasonic examination of the affected cat shows that the diameter of the large papilla of the duodenum is about 5mm (the normal diameter is less than 2.4 mm) from B ultrasonic scanning, which indicates that inflammation exists in pancreatic duct and bile duct; double signs of gallbladder, indicating cholecystitis; the duodenal mucosa layer is seen with a hyperechogenic bright line, indicating duodenal fibrosis. And (3) testing by adopting Edison cPL rapid test paper, wherein the result is positive. Indicating that the content of the plasma specific lipase exceeds the standard, the pancreatitis can be pointed.
The rehydration liquid maintains vascular perfusion, prevents shock, controls vomiting and secondary infection, relieves pain and treats the trisomy. Intravenous injection: sodium lactate ringer 50ml + compound butafos injection 1ml,5% glucose 50ml + gabexate mesylate 10mg (example 2), 5% glucose + vitamin B complex 1ml; subcutaneous injection: 0.5ml of anti-emetic agent. 40mg of amoxicillin and clavulanate potassium, 45mg of enrofloxacin and 1.5mg of butorphanol.
The test result is negative after rechecking the Edison cPL rapid test paper on the fifth day. Indicating that the plasma specific lipase content returns to normal. Through 10 days of hospitalization, vital signs are stable, mental conditions are improved, and appetite is restored. The prognosis of trisomy is greatly different, and pancreatitis needs to be consolidated and treated for a long time.
Catarrhal trisomy is a three disease association, possibly associated with an ascending infection of gastrointestinal bacteria. Because of the unique anatomy of cats, the pancreas is more susceptible to upstream infections by the pancreas in combination with bile ducts at the papilla prior to entry into the duodenum. It has been found that cats with cholangitis have a higher prevalence of pancreatitis and intestinal inflammation. Pancreatitis is associated with 60% of cats with cholangitis, and with 50% of cats with cholecystitis.
The foregoing description of the embodiments has been provided for the purpose of illustrating the general principles of the invention, and is not meant to limit the scope of the invention, but to limit the invention to the particular embodiments, and any modifications, equivalents, improvements, etc. that fall within the spirit and principles of the invention are intended to be included within the scope of the invention.
Claims (10)
1. The application of gabexate mesylate in preparing a pharmaceutical preparation for treating pancreatitis of pets is characterized in that the pharmaceutical preparation comprises the active ingredient gabexate mesylate and one or more than one pharmaceutical auxiliary materials.
2. The use according to claim 1, wherein said pancreatitis in pets is caused by one or more of a pancreatic susceptibility, a parasitic infectious disease, a veterinary clinical drug factor, a viral infectious disease, caused by a specific dietary structure or a pancreatic physiological structure of pets.
3. The application of gabexate mesylate in preparing a pharmaceutical preparation for treating complications of pancreatitis in pets is characterized in that the complications of pancreatitis in pets are one or more of cholangitis, biliary tract obstruction, inflammatory bowel disease, metabolic alkalosis and catarrhal trisomy.
4. Use according to claim 1 or 3, characterized in that the pharmaceutical preparation is gabexate mesylate fat emulsion injection.
5. The gabexate mesylate fat emulsion injection is characterized by comprising the following components in percentage by mass and volume: 1.0 to 3.0 percent of gabexate mesylate, 8 to 30 percent of oil for injection, 0.5 to 2.0 percent of lecithin and 3 to 10 percent of glycerol, and the water for injection is supplemented to 100 percent.
6. The gabexate mesylate fat emulsion injection according to claim 5, wherein the fat emulsion injection comprises the following components in percentage by mass and volume: 1.5 to 2.5 percent of gabexate mesylate, 8.0 to 15.0 percent of oil for injection, 1.0 to 2.0 percent of lecithin, 3.0 to 5.0 percent of glycerol and 100 percent of water for injection.
7. The gabexate mesylate fat emulsion injection according to claim 5 or 6, wherein the oil for injection is selected from one or more of soybean oil, olive oil, safflower oil, sesame oil, coconut oil, castor oil, fish oil, medium chain monoglyceride, medium chain diglyceride, medium chain triglyceride.
8. The gabexate mesylate fat emulsion injection according to claim 7, wherein the oil for injection is one or more selected from the group consisting of fish oil, medium chain triglycerides, soybean oil, castor oil.
9. A method for preparing the gabexate mesylate fat emulsion injection according to any one of claims 5 to 8, comprising the following steps:
(1) Preparing an oil phase: weighing the gabexate mesylate and the oil for injection according to the prescription, adding lecithin, heating to 70-90 ℃, and stirring and dissolving to obtain an oil phase;
(2) Preparing an aqueous phase: weighing the glycerol and the water for injection according to the prescription, heating to 70-90 ℃, stirring and dissolving to obtain a water phase;
(3) Adding the oil phase into the water phase while shearing at 7000rpm at high speed under the heat preservation condition of 70-90 ℃, and shearing for 20min after the addition is finished to form colostrum; the colostrum is processed by a high-pressure homogenizer for 2 times under the pressure of 800-1200 bar to obtain emulsion; packaging into penicillin bottles, filling nitrogen, sealing and sterilizing to obtain the final product.
10. The use according to claim 4, wherein the administration dose of the gabexate mesylate fat emulsion injection is 2 to 6mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211712037.8A CN117462527A (en) | 2022-12-29 | 2022-12-29 | Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211712037.8A CN117462527A (en) | 2022-12-29 | 2022-12-29 | Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117462527A true CN117462527A (en) | 2024-01-30 |
Family
ID=89628056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211712037.8A Pending CN117462527A (en) | 2022-12-29 | 2022-12-29 | Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117462527A (en) |
-
2022
- 2022-12-29 CN CN202211712037.8A patent/CN117462527A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2315975C (en) | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use | |
| TWI321053B (en) | Use of a botulinum toxin for the manufacture of a medicament for treating a pancreatic disorder | |
| JP2022123073A (en) | Method of treating or reducing efp | |
| JP2017061512A (en) | Liquid formulations | |
| EP2391382B1 (en) | Pharmaceutical preparation comprising lipase of bacterial origin | |
| MXPA03010022A (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis. | |
| JP2005525339A (en) | Compositions and methods for treating skin conditions | |
| CN105853454A (en) | Broad-spectrum antiparasitic drug nano-emulsion and preparation method thereof | |
| CN102119923B (en) | Antibiotic oil-water double suspension type injection emulsion for livestock and preparation method thereof | |
| WO2006034624A1 (en) | Process for preparing oil preparation of tetrodotoxin | |
| CN117462527A (en) | Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets | |
| TW201043231A (en) | Blood parasiticide | |
| Ivey et al. | Therapeutics for rabbits | |
| CN112121012B (en) | Preparation method and application of curcumin-oleic acid oral self-emulsifying agent for treating type I diabetes | |
| CN104797254B (en) | Pidotimod treats the purposes of atopic dermatitis | |
| CN103417477B (en) | A kind of take water as doractin O/W type injection of substrate and preparation method thereof | |
| RU2209074C2 (en) | Method for treating burns | |
| CN101669906B (en) | Praziquantel injection, preparation method and application thereof | |
| CN108524494A (en) | Application and potassium dehydroandrographolide succinate animal medicament of the potassium dehydroandrographolide succinate in preparing veterinary drug | |
| CN110665002B (en) | Antibody preparation for preventing and treating bovine viral diarrhea and preparation method thereof | |
| CN101375859A (en) | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock | |
| CN108434446B (en) | Liposome atomization therapeutic preparation containing acetaldehyde dehydrogenase and preparation method and application thereof | |
| Sirois | Mosby's Veterinary PDQ-E-Book: Veterinary Facts at Hand | |
| CN103181925A (en) | Compound febantel gel and preparation method thereof | |
| JP2007031387A (en) | Intestinal function accelerator and method of preventing necrotizing enterocolitis using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |